Why the study?
Although chronic kidney disease and acute kidney injury are linked to adverse outcomes after TAVR, little is known regarding the prognostic implications of renal function improvement after TAVR.
Does renal improvement after TAVR improve survival time in patients undergoing TAVR?
Does renal improvement after TAVR improve survival time in patients undergoing TAVR?
Renal improvement after TAVR is associated with a significant survival benefit specifically in high-risk patients, such as those with NYHA class IV or a high propensity for renal improvement.
Answers are grounded in this paper and cite their sources.
RI after TAVR was associated with survival benefit in a high-likelihood subgroup; leaves open whether this is causal or generalizable.
BACKGROUND: Chronic kidney disease as well as acute kidney injury are associated with adverse outcomes after transcatheter aortic valve replacement (TAVR). However, little is known about the prognostic implications of an improvement in renal function after TAVR. METHODS: Renal improvement (RI) was defined as a decrease in postprocedural creatinine in μmol/l of ≥1% compared to its preprocedural baseline value. A propensity score representing the likelihood of RI was calculated to define patient groups which were comparable regarding potential confounders (age, sex, BMI, NYHA classification, STS score, log. EuroSCORE, history of atrial fibrillation/atrial flutter, pulmonary disease, previous stroke, CRP, creatinine, hsTNT and NT-proBNP). The cohort was stratified into 5 quintiles according to this propensity score and the survival time after TAVR was compared within each subgroup. RESULTS: Patients in quintile 5 (n = 93) had the highest likelihood for RI. They were characterized by higher creatinine, lower eGFR, higher NYHA class, higher NT-proBNP, being mostly female and having shorter overall survival time. Within quintile 5, patients without RI had significantly shorter survival compared to patients with RI (p = 0.002, HR = 0.32, 95% CI = [0.15-0.69]). There was no survival time difference between patients with and without RI in the whole cohort (p = 0.12) and in quintiles 1 to 4 (all p > 0.16). Analyses of specific subgroups showed that among patients with NYHA class IV, those with RI also had a significant survival time benefit (p < 0.001, HR = 0.15; 95%-CI = [0.05-0.44]) compared to patients without RI. CONCLUSIONS: We here describe a propensity score-derived specific subgroup of patients in which RI after TAVR correlated with a significant survival benefit.
No takes yet. Share an insight, caveat, or question.
Kylies et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: